Dural Arteriovenous Fistulas Treatment Market Size was valued at USD 2.68 Billion in 2023. The Global Dural Arteriovenous Fistulas Treatment industry is projected to grow from USD 2.86 Billion in 2024 to USD 4.92 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.90% during the forecast period (2024 - 2032).
Dural arteriovenous fistulas (DAVF) is caused by abnormal connections between arteries and veins in a protective membrane on the outer layer of the brain and spine; it is a rare disease. These abnormal blood vessels divert blood from the normal paths. If the volume of diverted blood flow is large, tissue downstream may not receive an adequate blood and oxygen supply. The symptoms vary, depending on the location of fistulae. Headaches are among the most common symptoms with all types of DAVFs. Other symptoms include visual problems, ringing in ears, heart strokes, and others.
Increasing prevalence of brain injury and neurological disorders, increasing investment in biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the dural arteriovenous fistulas treatment market. Moreover, favorable reimbursement policies, increased applications, and significant investments in the development of advance technologies for the treatment methods likely to fuel the dural arteriovenous fistulas treatment market growth during the forecast period 2017-2023.
As per the Centers for Disease Control and Prevention in 2014, about 2.8 million TBI-related Emergency Department (ED) visits, hospitalizations, and deaths occurred in the United States. TBI (traumatic brain injury) contributed to the deaths of nearly 50,000 people. It was diagnosed in over 282,000 hospitalized cases and over 2.5 million ED visits. These consisted of TBI alone or TBI in combination with other injuries. Adults aged over 75 years have the highest rates of TBI-related hospitalization and deaths.
According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of gastrointestinal disorders, or cancers, and is expected to increase further over the coming years.
However, higher cost of these treatment procedure may hamper the dural arteriovenous fistulas treatment market growth during the corresponding period.
Medtronic, a multinational medical technology company, has been undertaking some projects on new endovascular devices to cure vascular conditions, including DAVF, since April 2021. Examples are the Pipeline Flex Embolization Device that re-routes blood away from DAVF and the Excelsior SL-10 Microcatheter, which assists in embolic agent delivery.
In May 2018, NYU Langone Health launched a cutting-edge multidisciplinary program called the Center for Stroke and Neurovascular Diseases with two locations in Manhattan and Brooklyn hospitals to address the complex needs of stroke patients as well as other cerebrovascular diseases. Notably, it is directed by Howard A. Riina MD, who stands out as a professor of neurosurgery, neurology, and radiology and also serves as vice chair of the Department of Neurosurgery, while Koto Ishida MD, who is an assistant professor of neurology doubles up as director of NYU Langone’s stroke program. The Center for Stroke and Neurovascular Diseases brings together key opinion leaders in fields like vascular neurology, neurosurgery, neurocritical care, and neuro-interventional radiology, among other related disciplines, into diagnosing and treating people with disorders involving vessels in the brain/spinal cord. It also offers recommendations on how to prevent these ailments to individuals at high risk.
Norwalk Hospital unveiled its biplane angiography suite equipped with state-of-the-art equipment for the diagnosis and treatment of neurological problems such as stroke and heart disease in July 2021. The biplane angiography system is made up of two cameras that revolve around each other, resulting in detailed three-dimensional X-ray images of soft tissues, blood flow through blood vessels, and details on internal structures like airways or lymph nodes. This system will be utilized by endovascular neurosurgeons together with cardiologists who will perform procedures such as opening occlusions within arteries so as to restore blood supply to tissues located inside the heart or brain through small cuts with higher precision. The biplane angiography system has also increased treatment and diagnostic options for vascular conditions as well as heart diseases that include atrial fibrillation, aneurysms, peripheral vascular disease, and coronary artery disease.
The dural arteriovenous fistulae treatment market is segmented on the basis of type, treatment, and end user.
On the basis of type, the dural arteriovenous fistulas treatment market is segmented into type I, type II, and type III.
On the basis of application, the dural arteriovenous fistulas treatment market is segmented into surgery, stereotactic radiosurgery, embolization, and others.
On the basis of end user, the dural arteriovenous fistulas treatment market is segmented into hospitals & clinics, ambulatory surgical centers, and others.
The Americas dominates the dural arteriovenous fistulas treatment market owing to developing technology, increasing cases of brain injury, rising prevalence of neurological disorders, growing healthcare spending, and increasing government support for research & development. Furthermore, increasing R&D activities and the presence of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the dural arteriovenous fistulas treatment market. It is expected that the government support for research & development and availability of funds for research may drive the market in European region over the review period.
Asia Pacific is the fastest growing dural arteriovenous fistulas treatment market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing new opportunities in countries such as China, India, Japan, and South Korea projected to emerge as the fastest growing market across the globe. Furthermore, increasing demand for the neurological treatment may lead to the use of advanced equipment, which, in turn, will increase the growth of the dural arteriovenous fistulas treatment market in the region.
On the other hand, the Middle East and Africa holds the least share of the market due to limited medical facilities, lack of funds for research and development, and poor political conditions, especially, in Africa.
Key Players
Some of key the players in the dural arteriovenous fistulas treatment market are
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | 2032: USD 4.92 Billion |
| CAGR | 7.90% |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, and End user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | BD (U.S.), Medtronic (U.S.), B. Braun Melsungen AG (Germany), Cook (U.S.), Teleflex Incorporated (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), NxStage Medical, Inc.(U.S.), and Poly Medicure Limited |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | · Increasing prevalence of brain injury and neurological disorders · Increasing investment in biotechnology and pharmaceutical industries in R&D · Rising need for the better treatment methods |
Dural Arteriovenous Fistulas Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
Dural arteriovenous fistulae treatment market is projected to grow at approximately 7.90% CAGR during the assessment period (2024-2032).
Increasing prevalence of brain injury & neurological disorders, rising per capita healthcare expenditure, and increasing investment in biotechnology & pharmaceutical industries.
Higher cost and reported cases of side effects associated with these treatment procedures are major growth impeders for the global dural arteriovenous fistulae treatment market.
North America holds the largest share in the global dural arteriovenous fistulae treatment market, followed by Europe and the Asia Pacific, respectively.
BD (U.S.), B. Braun Melsungen AG (Germany), Medtronic (U.S.), Cook (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), Teleflex Incorporated (U.S.), NxStage Medical, Inc.(U.S.), and Poly Medicure Limited, are some of the top players operating in the global dural arteriovenous fistulae treatment market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
